Louis Nabors
Neurology · Birmingham, ALNPI 1225068620
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $7,650 of the $10,080 with a category attached, or 75.9%. 7 manufacturers reported payments, led by BTG International Inc. at 59.5% of the total. Reporting peaked in 2019 at $8,469 and has fallen 99.8% since, to $14 in 2025.
Across 12 payments — averaging $839.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- BTG International Inc.$6K
- Blue Earth Diagnostics$2K
- Biogen$800
- Servier Pharmaceuticals LLC$699
- AstraZeneca$69
- Taiho Oncology, Inc.$28
- plus $14 from 1 others
Across 356 payments — averaging $8976.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Servier Bioinnovation$2.5M
- E.r. Squibb & Sons, L.L.C.$228K
- Servier Pharmaceuticals LLC$142K
- Karyopharm Therapeutics Inc.$131K
- Merck$116K
- Agios Pharmaceuticals, Inc.$48K
- plus $8K from 2 others
What the payments were for
- Consulting fees$8008%
- Speaking & faculty fees$7,65076%
- Travel & lodging$6787%
- Food & beverage$9529%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| BTG International Inc. | 4 | $5,994 |
| Blue Earth Diagnostics | 1 | $2,475 |
| Biogen | 1 | $800 |
| Servier Pharmaceuticals LLC | 3 | $699 |
| AstraZeneca | 1 | $69 |
| Taiho Oncology, Inc. | 1 | $28 |
| Caris MPI, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,080 in reported general payments places this provider in the 65th percentile of 255 neurology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GleostineLomustine | 13 | $14,372 |
| Lacosamide | 38 | $2,497 |
| Levetiracetam | 37 | $758 |
| Gabapentin | 52 | $353 |
| Methylphenidate Hcl | 14 | $317 |
| Dexamethasone | 20 | $296 |
| Ondansetron Hcl | 11 | $49 |
| Prednisone | 14 | $44 |
| Clonazepam | 14 | $33 |
| Lorazepam | 14 | $16 |
Paid to pharmacies, not to this prescriber.
Other neurology in Birmingham
- Diane CounceBirmingham$895K
- Emily RiserBirmingham$231K
- Wesley KingBirmingham$167K
- Jerzy SzaflarskiBirmingham$164K
- Victor SungBirmingham$138K
- Raymond FaughtBirmingham$99K
- David GeldmacherBirmingham$99K
- David StandaertBirmingham$82K
- Richard DiethelmBirmingham$65K
- Mina LobbousBirmingham$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.